Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity

International Journal of Obesity

Volumn 32, Issue 3, 2008, Pages 436-442

  Wu, M K ^a,b   Huang, C Y ^c   Liou, Y J ^a   Wang, C K ^b   Lee, S D ^c  

^a YULI VETERANS HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

HOMA index; Hormonal; Metabolic; Psychiatric; Schizophrenia

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE HOMEOSTASIS; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHTS AND MEASURES; CLOZAPINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; SCHIZOPHRENIA;

EID: 40949132976     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803750     Document Type: Article

References (39)

1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93.
2. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter Jr WT. Adverse effects and laboratory parameters of high-dose olanzapine vs clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003; 15: 181-186.
3. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA et al. Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 173-180.
4. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004; 26: 1936-1946.
5. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219-2229.
6. Bunce II DF, Jones LR, Badger LW, Jones SE. Medical illness in psychiatric patients: barriers to diagnosis and treatment. South Med J 1982; 75: 941-944.
7. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60 (Suppl 21): 10-15.
8. Nasrallah HA. Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr 2003; 8 (11 Suppl 2): 23-25.
9. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin psychiatry 2002; 63: 856-865.
10. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003; 170: 157-166.
11. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003; 59: 49-57.
12. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J psychiatry 2002; 159: 561-566.
13. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agent. Arch Gen Psychiatry 2005; 62: 19-28.
14. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161: 361-363.
15. Gualin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglyceride. Am J psychiatry 1999; 156: 1270-1272.
16. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J health Syst Pharm 1996; 53: 2079-2081; prospective study.
17. Opgaard OS, Wang PH. IGF-1 is a matter of heart. Growth Horm. IGF Res 2005; 15: 89-94.
18. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31: 2049-2061.
19. Bleumink GS, Rietveld I, Janssen JA, van Rossum EF, Deckers JW, Hofman A et al. Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol 2004; 94: 384-386.
20. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 619-637.
21. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005; 90: 5937-5941.
22. Colao A, Spiezia S, Di Somma C, Pivonello R, Marzullo P, Rota F et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28: 440-448.
23. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944.
24. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783-791.
25. Khosravi MJ, Papanastasiou-Diamandi A, Mistry J. An ultrasensitive immunoassay for prostate-specific antigen based on conventional colorimetric detection. Clin Biochem 1995; 28: 407-414.
26. Wu MK, Bai YM, Huang CY, Wang CK, Lee SD. Outcomes of obese, clozapine-treated impatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatric Service 2007; 58: 544-550.
27. Sharpe JK, Hills AP. Anthropometry and adiposity in a group of people with chronic mental illness. Aust N Z J Psychiatry 1998; 32: 77-81.
28. Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psychiatry 1998; 43: 520-524.
29. Bjorntorp P. Obesity and risk of cardiovascular disease. Acta Med Scand 1985; 218: 145-147.
30. Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005; 118 (Suppl 2): 3S-8S.
31. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004; 6: 74-77.
32. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006; 84: 1-14.
33. Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr 2003; 8 (11 Suppl 2): 19-22.
34. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73.
35. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994; 43: 315-319.
36. Melkersson KI, Scordo MG, Gunes A, Dahl ML. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007; 68: 697-704.
37. Dunger D, Yuen K, Ong K. Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004; 62 (Suppl 1): 101-107.
38. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K. Altered relation between circulating levels of insulin-like growth factors-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646-2652.
39. Howes OD, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. The effect of clozapine on factors controlling glucose homeostasis. J Clin Psychiatry 2004; 65: 1352-1355.